PLAU and prostate cancer: Furthermore, siRNA-mediated PTPN13 silencing in the PC3 and DU145 prostate cancer cell lines leads to overexpression of urokinase-type plasminogen activator (uPA) fibrinolytic system components that can degrade the extracellular matrix, thus promoting tumor invasion [93].